In Massachusetts, InVivo Therapeutics Holdings Corp., a biomaterials and biomedicals company focused on spinal cord injuries, hired Christopher McNulty as CFO as of March 29th. McNulty was a former SVP of Business Development and Investor Relations at InVivo and worked directly on a follow-on offering and direct financing projects. Prior to InVivo, he worked at Repligen leading its acquisition of Novozymes Sweden, and seemingly is a jack of all trades with degrees in electrical engineering and computer science from MIT as well as an MBA from Harvard. Melanie Morel-Ferris has been serving as the interim CFO and will stay on as Senior Director of Finance and Controller.
Latest article
Biobased sunglasses assist British special forces team with record-breaking Everest trek
In Nepal, four former British special forces soldiers were outfitted with bioplastic sunglasses from Teysha Technologies as they set a mountaineering record for traveling...
Diaper duty development: Hiro unveils nappy-eating fungi
In Texas, a startup has introduced a new diaper concept that aims to address one of the biggest challenges parents face: balancing sustainability with...
von Holzhausen creates “Ripple shoe” from proprietary renewable material
In California, sustainable material firm von Holzhausen has made a 100% biodegradable and plastic-free shoe from Liquidplant™, a polyurethane-like material developed in house out...